A Phase I Study of SGN-CD352A in Patients with Recurrent or Persistent Multiple Myeloma

Full Title

SGN352-001: Phase 1 Study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma


The purpose of this study is to find the highest dose of the investigational drug SGN-CD352A that can be given safely in patients with multiple myeloma that has come back or continued to grow despite treatment, and to observe its preliminary effectiveness against this cancer. SGN-CD352A is called an antibody-drug conjugate (ADC): it consists of an anticancer drug attached to an antibody that binds to a protein called CD352.

CD352 is an important part of some cancer cells and some normal cells of the immune system. Once the antibody part of SGN-CD352A sticks to CD352 on the myeloma cell, the ADC goes inside the cell. There the chemotherapy is released and may kill the cell. SGN-CD352A is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that came back or continued to grow despite at least two prior regimens of therapy.
  • At least 4 weeks must pass between the completion of prior treatment and entry into the study (or 2 weeks if the cancer is still growing and patients have recovered from the serious side effects of therapy).
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Ola Landgren at 212-639-5126.





Disease Status

Relapsed or Refractory